Altered polypeptides with increased half-life
AssigneeGenentech, Inc.
InventorsLeonard G. Presta, Bradley R. Snedecor
Life of this patent
Estimating the term…
Abstract
Polypeptides that are cleared from the kidney and do not contain in their original form a Fc region of an IgG are altered so as to comprise a salvage receptor binding epitope of an Fc region of an IgG and thereby have increased circulatory half-life.
Claims7
A method for preparing a variant polypeptide of interest, wherein the polypeptide of interest is a Fab or a (Fab').sub.2 which contains an Ig domain or Ig-like domain comprising at least one of a CH1 or C.sub.L, region, that is cleared from the kidney and does not contain a Fc region of an IgG, comprising:
- altering said polypeptide of interest within the CH1 or C.sub.L, region to contain a salvage receptor binding epitope taken from two loops of a CH2 domain of an Fc region of an IgG, and wherein said altering results in an increased in vivo half-life.
A method for preparing a variant polypeptide of interest, wherein the polypeptide of interest is an anti-CD18 Fab or anti-CD18 (Fab').sub.2 which contains an Ig domain or Ig-like domain comprising at least one of a CH1 or C.sub.L, region, that is cleared from the kidney and does not contain a Fc region of an IgG, comprising:
- altering said polypeptide of interest within the CH1 or C.sub.L region to contain a salvage receptor binding epitope taken from two loops of a CH2 domain of an Fc region of an IgG, and wherein said altering results in an increased in vivo half-life.
Dependencies are inferred from the claim text.